Entasis Therapeutics Appoints David C. Hastings to Board of Directors
WALTHAM, Mass. – May 1, 2018 – Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the appointment of…